HIV TREATMENT GUIDELINE COMPLIANCE AMONG TREATMENT-NAÏVE MISSISSIPPI MEDICAID ADULT BENEFICIARIES

Objectives: Research has consistently demonstrated the effectiveness of antiretroviral therapy (ART) in reducing HIV-related morbidity and mortality. Current guidelines for the treatment of HIV identify specific combination regimens with medications from two different drug classes. The objective of this study was to assess compliance with these guidelines among treatment-naïve individuals.

Methods: Mississippi Medicaid prescription claims data (January 2008 to October 2011) were analyzed for beneficiaries who met eligibility criteria: age >17, not pregnant, and enrolled in Medicaid for at least three months prior to the index prescription date. Beneficiaries were considered treatment-naïve and starting initial therapy if no ART claims existed for at least three months prior to the first ART claim. We defined a guideline-adherent ART regimen as use of a minimum of three drugs including two nucleoside reverse transcriptase inhibitors (NRTIs) in combination with one protease inhibitor (PI) or one nonnucleoside reverse transcriptase inhibitor (NNRTI) between July 2008 and December 2010. Between January 2010 and November 2011, a guideline-adherent ART regimen could also include two NRTIs in combination with one integrase inhibitor.

Results: A total of 604 beneficiaries met inclusion criteria. Between July 2008 and December 2009, 39.8% and 25.5% of beneficiaries were on an NNRTI-based regimen and PI-based regimen, respectively. Additionally, 4.4% met more than one guideline simultaneously. Approximately 30.3% were prescribed a medication regimen that was not in accordance with guidelines. Between January 2010 and October 2011, 38.8% and 24.1% of beneficiaries were on an NNRTI-based regimen and PI-based regimen, respectively. Additionally, 5.3% met more than one guideline simultaneously. Approximately 25.5% were prescribed a medication regimen that was not in accordance with guidelines.

Conclusions: During the study period, the majority of beneficiaries were in accordance with treatment guidelines for initial therapy for treatment-naïve patients with minimal temporal changes across the three primary combination regimens.

AUTHORS: Przybyla SM¹, Banahan BF III¹,², Null KD¹, Hardwick SP³, Clark JP³

¹Center for Pharmaceutical Marketing and Management, University of Mississippi.
²Department of Pharmacy Administration, School of Pharmacy, University of Mississippi.
³Mississippi Division of Medicaid.
**Acknowledgement:** The work reported was conducted by the MS-DUR program in the Center for Pharmaceutical Marketing and Management as part of the retrospective drug use analysis activities conducted under contract with the Mississippi Division of Medicaid. The views expressed are those of the authors and do not necessarily reflect those of Mississippi Division of Medicaid or the University of Mississippi.